摘要
目的观察标准化粉尘螨滴剂舌下特异性免疫治疗(SLIT)对多重过敏的过敏性哮喘(AS)的疗效及安全性。方法收集接受规则治疗2年且随访资料完整的轻、中度AS患者141例,按皮肤点刺试验结果及患者治疗意愿,分为单一尘螨过敏免疫治疗组(单一免疫组)41例、多重过敏免疫治疗组(多重免疫组)51例和多重过敏常规治疗组(多重常规组)49例。3组均应用小至中等剂量的吸入型糖皮质激素+长效β2受体激动剂,免疫组在此基础上给予粉尘螨滴剂SLIT,进行2年的随访观察,评价疗效。结果治疗2年后,多重免疫组的症状评分、用药评分显著低于多重常规组,ACT评分显著高于多重常规组(P<0.05)。治疗2年后,多重免疫组的各项指标与单一免疫组比较差异均无统计学意义(P>0.05)。多重免疫组与SLIT有关的不良反应发生率为9.80%,与单一免疫组类似(9.76%)。结论标准化粉尘螨滴剂综合药物治疗多重过敏的AS患者,较常规药物更能明显改善哮喘症状,减少药物使用,提高哮喘控制水平,可达到单一过敏患者的相似的治疗效果,未发生严重不良反应。
Objective To evaluate the efficacy of sublingnal immunotherapy （SLIT） with dermatophagoides farinae drops in polysensitized patients with allergic asthma （AS）. Methods 141 AS patients who were treated standardized for 2 years with complete clinical data were collected. They were divided into the monoallergen sensitized and SLIT group （n =41 ）, the polyallergen sensitized and SLIT group （n = 51 ）, and the polyallergen sensitized and routine treatment group （ n = 49） according to the results of skin prick tests and patient willingness. All patients were treated with low to moderate dose of glucocorticoid and long-effect 132 agonists, and the patients in two SLIT groups were treated with SLIT of dermatophagoides farinae drops on this basis. Results 2 years after the treatment, the symptom score and medication score in the polyallergen sensitized and SLIT group were significantly lower than those in the polyallergen sensitized and routine treatment group （P 〈 0. 05）. ACT score in the polyallergen sensitized and SLIT group was significantly higher than those in the polyallergen sensitized and routine treatment group （ P 〈 0. 05 ）. There were no significant difference in the symptom score, medication score and ACT score between the monoallergen sensitized and SLIT group and the polyallergen sensitized and SLIT group （ P 〉 0. 05 ）. The incidence of adverse reaction in the polyallergen sensitized and SLIT group （9. 80% ） was similar with that in the monoallergen sensitized and SLIT group （9. 76% ） （P 〉 0.05 ）. Conclusion SLIT with dermatophagoides farinae drops is more effective than routine treatment, and equivalent efficacy could be achieved compared with monosensitized patients after 2 years.
出处
《临床肺科杂志》
2016年第7期1194-1198,共5页
Journal of Clinical Pulmonary Medicine
基金
广西梧州市科技计划项目(No 201202081)
关键词
舌下含服
特异性免疫治疗
粉尘螨
哮喘
sublingual administration
immunotherapy
dermatophagoides farina
allergic asthma
